Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
前收盘价
US$27.24
+US$0.28 · +1.04%
盘前
US$27.45
+US$0.21 · +0.77%
10月12日 8:23 ET
盘中时间采用ET。市场数据可能有所延迟。
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
日内区间
当前US$27.24
52周区间
当前US$27.24
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
买入
估值
88
深度低估
情绪
58
多空交织
风险
32
中等风险
动量
45
中性
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
日内区间
当前US$27.24
52周区间
当前US$27.24
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 61.64亿 USD | 58.1亿 USD | 55.49亿 USD | 52.15亿 USD | 52.12亿 USD |
| 销货成本 | 19.57亿 USD | 17.31亿 USD | 16.54亿 USD | 15.15亿 USD | 15.14亿 USD |
| 毛利 | 42.07亿 USD | 40.79亿 USD | 38.95亿 USD | 37亿 USD | 36.98亿 USD |
| 研究与开发 | 3.46亿 USD | 3.43亿 USD | 3.39亿 USD | 3.45亿 USD | 3.56亿 USD |
| 销售、一般及管理费用 | 30.36亿 USD | 29.04亿 USD | 28.34亿 USD | 27.07亿 USD | 26.37亿 USD |
| 营业费用 | 34.13亿 USD | 34.22亿 USD | 34.7亿 USD | 32.5亿 USD | 31.05亿 USD |
| 利息收入 | 2806.54万 USD | 2401.01万 USD | 3413.18万 USD | 1399.14万 USD | 599.93万 USD |
| 利息支出 | 1.41亿 USD | 1.5亿 USD | 1.33亿 USD | 7995.06万 USD | 7999.05万 USD |
| 折旧和摊销 | 5.73亿 USD | 5.55亿 USD | 5.27亿 USD | 5.48亿 USD | 5.63亿 USD |
| 营业利润 | 7.94亿 USD | 6.57亿 USD | 4.25亿 USD | 4.5亿 USD | 5.93亿 USD |
| 净利润 | 6.25亿 USD | 4.12亿 USD | 2.63亿 USD | 2.23亿 USD | 5.24亿 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$31.91
上涨空间 17.14%年度分割调整后的每股现金分配。
US$0.762
2025年(完整年度)+1.6% 自从 2021
2026年(部分年度):US$0.794
US$0.75
2,021
US$0.75
2,022
US$0.75
2,023
US$0.75
2,024
US$0.762
2,025
US$0.794
2,026*
* 在现有股息历史记录中,该日历年仅包含部分期间。
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2026年10月2日 | US$0.312Semi-Annual | 2026年10月2日 | 2026年11月6日 |
股息 | 2026年3月27日 | US$0.482Semi-Annual | 2026年3月27日 | 2026年5月27日 |
股息 | 2025年10月3日 | US$0.30Semi-Annual | 2025年10月3日 | 2025年11月7日 |
股息 | 2025年3月28日 | US$0.462Semi-Annual | 2025年3月28日 | 2025年5月28日 |
股息 | 2024年10月4日 | US$0.288Semi-Annual | 2024年10月4日 | 2024年11月8日 |
股息 | 2024年4月1日 | US$0.462Semi-Annual | 2024年4月2日 | 2024年5月22日 |
除息 2026年10月2日
US$0.312
Semi-Annual
2026年10月2日登记 · 支付日 2026年11月6日
除息 2026年3月27日
US$0.482
Semi-Annual
2026年3月27日登记 · 支付日 2026年5月27日
除息 2025年10月3日
US$0.30
Semi-Annual
2025年10月3日登记 · 支付日 2025年11月7日
除息 2025年3月28日
US$0.462
Semi-Annual
2025年3月28日登记 · 支付日 2025年5月28日
除息 2024年10月4日
US$0.288
Semi-Annual
2024年10月4日登记 · 支付日 2024年11月8日
除息 2024年4月1日
US$0.462
Semi-Annual
2024年4月2日登记 · 支付日 2024年5月22日
报告持有此股票敞口的交易所交易基金。
Vanguard Total International Stock ETFVXUS1071.02万0.00%6657亿 USD0.05%US$84.82+0.86%
Vanguard FTSE Emerging Markets ETFVWO1045.3万0.01%1685亿 USD0.06%US$59.76+1.12%
Dimensional - International Core Equity 2 ETFDFIC802.49万0.05%150.17亿 USD0.22%US$37.53+0.64%
Avantis International Equity ETFAVDE734.44万0.04%192.24亿 USD0.23%US$89.80+0.58%
Dimensional World ex U.S. Core Equity 2 ETFDFAX488.23万0.04%123.36亿 USD0.28%US$37.08+0.76%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP213.59万0.08%26.06亿 USD0.20%US$66.35+1.13%
Vanguard FTSE All-World ex-US ETFVEU171.93万0.00%986亿 USD0.04%US$82.82+0.78%
Vanguard International High Dividend Yield ETFVYMI85.89万0.00%228亿 USD0.07%US$100.66+0.60%
Vanguard Total International Stock ETFVXUS
Vanguard FTSE Emerging Markets ETFVWO
Dimensional - International Core Equity 2 ETFDFIC
Avantis International Equity ETFAVDE
Dimensional World ex U.S. Core Equity 2 ETFDFAX
State Street SPDR S&P Kensho New Economies Composite ETFKOMP
Vanguard FTSE All-World ex-US ETFVEU
Vanguard International High Dividend Yield ETFVYMIAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。